Kenneth Hillan

2021

In 2021, Kenneth Hillan earned a total compensation of $3.2M as Chief Therapeutics Officer at 23andMe Holding Co..

Compensation breakdown

Option Awards$2,671,454
Salary$554,960
Other$2,658
Total$3,229,072

Hillan received $2.7M in option awards, accounting for 83% of the total pay in 2021.

Hillan also received $555K in salary and $2.7K in other compensation.

Rankings

In 2021, Kenneth Hillan's compensation ranked 4,147th out of 12,415 executives tracked by ExecPay. In other words, Hillan earned more than 66.6% of executives.

ClassificationRankingPercentile
All
4,147
out of 12,415
67th
Division
Manufacturing
1,708
out of 5,505
69th
Major group
Chemicals And Allied Products
707
out of 2,375
70th
Industry group
Drugs
629
out of 2,096
70th
Industry
Pharmaceutical Preparations
443
out of 1,546
71st
Source: SEC filing on July 15, 2022.

Hillan's colleagues

We found three more compensation records of executives who worked with Kenneth Hillan at 23andMe Holding Co. in 2021.

2021

Anne Wojcicki

23andMe Holding Co.

Chief Executive Officer

2021

Steve Schoch

23andMe Holding Co.

Chief Financial Officer

2021

Kathy Hibbs

23andMe Holding Co.

Chief Administrative Officer

News

In-depth

You may also like